RLAY vs. BHC, AGIO, TWST, INDV, RXRX, DNLI, BEAM, KNSA, BLTE, and CNTA
Should you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Bausch Health Cos (BHC), Agios Pharmaceuticals (AGIO), Twist Bioscience (TWST), Indivior (INDV), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Kiniksa Pharmaceuticals International (KNSA), Belite Bio (BLTE), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry.
Relay Therapeutics vs. Its Competitors
Bausch Health Cos (NYSE:BHC) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.
Bausch Health Cos has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.
In the previous week, Relay Therapeutics had 4 more articles in the media than Bausch Health Cos. MarketBeat recorded 6 mentions for Relay Therapeutics and 2 mentions for Bausch Health Cos. Relay Therapeutics' average media sentiment score of 1.00 beat Bausch Health Cos' score of 0.17 indicating that Relay Therapeutics is being referred to more favorably in the news media.
78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 8.1% of Bausch Health Cos shares are held by company insiders. Comparatively, 4.9% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Bausch Health Cos has higher revenue and earnings than Relay Therapeutics. Bausch Health Cos is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.
Relay Therapeutics has a net margin of 0.00% compared to Bausch Health Cos' net margin of -0.41%. Relay Therapeutics' return on equity of -44.17% beat Bausch Health Cos' return on equity.
Bausch Health Cos presently has a consensus target price of $7.30, suggesting a potential upside of 13.44%. Relay Therapeutics has a consensus target price of $17.67, suggesting a potential upside of 376.83%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relay Therapeutics is more favorable than Bausch Health Cos.
Summary
Relay Therapeutics beats Bausch Health Cos on 11 of the 16 factors compared between the two stocks.
Get Relay Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Relay Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RLAY) was last updated on 7/17/2025 by MarketBeat.com Staff
